The most common adverse reactions experienced by patients who received<unk>  in the pooled placebo-controlled Phase III studies were abdominal pain (15.6% versus 12.5% on placebo), diarrhoea (12.8% versus 9.6% on placebo), dizziness (9.2% versus 1.0% on placebo), rash (12.8% versus 6.7% on placebo), upper respiratory tract reactions (including upper respiratory tract infection, nasal congestion, pharyngeal erythema, oropharyngeal pain, rhinitis, sinus congestion, and nasopharyngitis) (63.3% versus 50.0% on placebo), headache (23.9% versus 16.3% on placebo) and bacteria in sputum (7.3% versus 3.8% on placebo). One patient in the<unk>  group reported a serious adverse reaction: abdominal pain.
Ivacaftor
Lifitegrast
Roxadustat
Arformoterol
Formoterol
Zafirlukast
Lumacaftor/ivacaftor
Fluticasone